Evolving Practices for Myelodysplastic Syndromes (MDS): Highlights from ASH 2024 and Beyond - Episode 2

MDS Treatment Strategies: From Risk Assessment to Transplantation

, ,

Panelists discuss how the primary therapeutic goals for patients with intermediate- to high-risk myelodysplastic syndromes (MDS) focus on extending survival and modifying disease course through intensive treatments like hypomethylating agents or stem cell transplantation while addressing unique challenges such as treatment resistance, poor response durability, and limited options after hypomethylating agents failure.

Video content above is prompted by the following:

  • What is the goal of therapy for patients with intermediate- to high-risk MDS?
  • What unmet needs/challenges exist for treating patients with MDS?
  • In what ways does your treatment approach differ for patients with lower-risk MDS?